Biocept (BIOC) Given News Impact Rating of 0.12
News headlines about Biocept (NASDAQ:BIOC) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biocept earned a news impact score of 0.12 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 45.4163133414499 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
BIOC has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Biocept from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Monday, January 15th. Chardan Capital restated a “buy” rating and set a $1.50 target price (down previously from $2.50) on shares of Biocept in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $1.75.
Biocept (BIOC) traded up $0.01 during midday trading on Wednesday, reaching $0.30. 1,072,700 shares of the company’s stock were exchanged, compared to its average volume of 2,141,865. Biocept has a 12 month low of $0.26 and a 12 month high of $2.75. The company has a market cap of $18.55, a PE ratio of -0.34 and a beta of 1.98. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.27 and a current ratio of 1.41.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2018/02/14/biocept-bioc-given-news-impact-rating-of-0-12.html.
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.